Kazuhiko Yoshida

20PUBLICATIONS

23CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersRadiation therapyPanel data analysis

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (20)

Sort by Publication Date:

|May 07, 2026

Comparison of clinical outcomes of cabozantinib plus nivolumab and lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinoma.

|Mar 02, 2026

Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma.

Hiroki Ishihara, Koichi Nishimura, Yuki Nemoto

|Feb 06, 2026

Clinical evaluation of medical and surgical complete responses in metastatic renal cell carcinoma treated with immune checkpoint inhibitor combination therapy.

Kazuhiko Yoshida, Tsunenori Kondo, Junpei Iizuka

|Jan 27, 2026

Non-Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors.

Hiroki Ishihara, Yu-Yu Liu, Riu Yamashita

|Dec 18, 2025

Treatment Profile of First-Line Immune Checkpoint Inhibitor Combination Therapy for Advanced Renal Cell Carcinoma in Patients With End-Stage Renal Disease on Dialysis.

Hiroki Ishihara, Yuki Nemoto, Shinsuke Mizoguchi

|Sep 30, 2025

Impact of starting dose of tyrosine kinase inhibitors on outcomes following combination therapy of immune checkpoint inhibitors with tyrosine kinase inhibitors for previously untreated advanced renal cell carcinoma.

Hiroki Ishihara, Koichi Nishimura, Yuki Nemoto

Pageof 4

Frequent Collaborators

17 joint publications

Toshio Takagi

13 joint publications

Hiroki Ishihara

Tsunenori Kondo

Yuki Kobari

Hironori Fukuda

Yuki Nemoto

Yudai Ishiyama

Yu-Yu Liu

Riu Yamashita

Yukihiro Mizoguchi

Frequent Collaborators

17 joint publications

Toshio Takagi

13 joint publications

Hiroki Ishihara

7 joint publications

Tsunenori Kondo

2 joint publications

Yuki Kobari